Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 37Active not recruiting 13Terminated 12Withdrawn 7Unknown 5Recruiting 4No longer available 3Not yet recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Dermatologic 5

Conditions

Melanoma 5Thyroid Neoplasms 3Neoplasms 3Colorectal Neoplasms 2Solid Tumor 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1

Interventions

Nivolumab 23pembrolizumab 19Ipilimumab 13toripalimab 12Temozolomide 11Biopsy 8Dacarbazine 7Blood Specimen Collection 6trametinib 5dabrafenib 5camrelizumab 5atezolizumab 5Gene Expression Profiling 5Cyclophosphamide 5Chemotherapy, Adjuvant 5fludarabine 4durvalumab 4binimetinib 4aldesleukin 4Injections 4tislelizumab 3palbociclib 3encorafenib 3apatinib 3Sorafenib 3Introns 3Interleukin-2 3Drug Therapy 3Cisplatin 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × Melanoma × trametinib × Clear all
NCT02858921 2023-08-30

Neo Trio

Melanoma Institute Australia

Phase 2 Unknown
60 enrolled
Dermatologic

Melanoma, Neoplasms

NCT05171374 2022-06-01

RATIONALE

MelanomaPRO, Russia

Unknown
500 enrolled
Dermatologic

Melanoma

NCT03754179 2021-04-28

COMBI-R2

Universitair Ziekenhuis Brussel

Phase 1/2 Unknown
63 enrolled
Dermatologic

Melanoma

NCT03088176 2020-10-12

Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

West Cancer Center

Phase 1 Unknown
4 enrolled
Dermatologic

Melanoma

NCT02625337 2017-09-15

IMPemBra

The Netherlands Cancer Institute

Phase 2 Unknown
32 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡